Provided by Tiger Fintech (Singapore) Pte. Ltd.

EyePoint

6.10
-0.0900-1.45%
Pre-market: 6.540.4400+7.21%04:02 EDT
Volume:484.30K
Turnover:2.97M
Market Cap:419.25M
PE:-2.62
High:6.30
Open:6.12
Low:5.98
Close:6.19
Loading ...

EyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for Duravyu

Dow Jones
·
29 Oct 2024

EyePoint Pharmaceuticals’ Positive Clinical Data Boosts Buy Rating Amid Promising Eye Disease Therapies

TIPRANKS
·
28 Oct 2024

EyePoint Pharmaceuticals Inc : Jefferies Raises Target Price to $27 From $15

THOMSON REUTERS
·
28 Oct 2024

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday

Benzinga
·
28 Oct 2024

BUZZ-EyePoint rises after positive data from eye disease drug trial

Reuters
·
28 Oct 2024

EyePoint Pharmaceuticals Shares up 25% After Co Reports Interim Mid-Stage Data for Experimental Eye Disease Drug

THOMSON REUTERS
·
28 Oct 2024

BRIEF-Eyepoint Pharmaceuticals Announces Positive Interim 16-Week Data For Ongoing Phase 2 Verona Clinical Trial Of Duravyu For Diabetic Macular Edema

Reuters
·
28 Oct 2024

EyePoint announces interim 16-week data for ongoing Phase 2 VERONA trial

TIPRANKS
·
28 Oct 2024

EyePoint Pharmaceuticals Inc - Full Topline Data Expected in Q1 2025

THOMSON REUTERS
·
28 Oct 2024

EyePoint Pharmaceuticals Inc: Favorable Safety Profile Continues With No Duravyu-Related Ocular or Systemic Saes to Date

THOMSON REUTERS
·
28 Oct 2024

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 Verona Clinical Trial of Duravyu™ for Diabetic Macular Edema

THOMSON REUTERS
·
28 Oct 2024

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

GlobeNewswire
·
28 Oct 2024

Positive Outlook for EyePoint Pharmaceuticals Amid Promising Phase 3 Trials for Duravyu

TIPRANKS
·
25 Oct 2024

EyePoint Pharmaceuticals Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Oct 2024

Positive Outlook for EyePoint Pharmaceuticals: Phase 3 LUGANO Trial for DURAVYU Boosts Buy Rating

TIPRANKS
·
25 Oct 2024

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 Lugano Clinical Trial of Duravyutm for the Treatment of Wet Age-Related Macular Degeneration

THOMSON REUTERS
·
24 Oct 2024